Group Quarterly Statement

as of March 31, 2026



MEDIOS

Key financials (IFRS)



€ 527.6 million

Revenue

€ 21.2 million

EBITDA, adjusted for special items[1]



€ 12.5 million

Cash flow from operating activities

		Q1 2026	Q1 2025	Δ in %
Revenue	**€ thousand**	**527,621**	**484,657**	**8.9**
EBITDA	**€ thousand**	**19,092**	**21,762**	**–12.3**
Margin (as a % of revenue)	%	3.6	4.5	–0.9 PP
EBITDA, without extraordinary expenses[1]	**€ thousand**	**21,225**	**23,053**	**–7.9**
Margin (as % of revenue)	%	4.0	4.8	–0.8 PP
EBIT	**€ thousand**	**9,735**	**12,309**	**–20.9**
Margin (as % of revenue)	%	1.8	2.5	–0.7 PP
Consolidated earnings after tax	**€ thousand**	**4,963**	**6,384**	**–22.3**
Earnings per share (in €)		**0.20**	**0.25**	**–20.0**
Adjusted earnings per share[2]		**0.44**	**0.46**	**–4.3**
Cash flow from operating activities	**€ thousand**	**12,480**	**3,563**	**>100**
Capital expenditure (CapEx)	€ thousand	–2,594	–1,247	>100
Free cash flow (before M&A)[3]	€ thousand	9,886	2,316	>100
		31.03.2026	31.12.2025	
Total assets	**€ thousand**	**918,226**	**903,041**	**1.7**
Equity	€ thousand	519,696	514,219	1.1
Equity ratio (as %)	%	56.6	56.9	–0.3 PP
Debt-to-equity ratio		**1.2**	**1.3**	**–7.7**
Employees	**Number**	**993**	**1,037**	**–4.2**

		Q1 2026	Q1 2025	Δ in %
1 Special effects	**€ thousand**	**2,133**	**1,292**	**65.0**
Expenses from Stock Options Programs	€ thousand	245	211	16.3
Other expenses M&A	€ thousand	260	9	>100
ERP implementation costs	€ thousand	1,543	1072	43.9
One-time special expenses related to the change in the Executive Board	€ thousand	84	0	n/a

		Q1 2026	Q1 2025	Δ in %
2 Adjusted earnings per share				
Net income after taxes	€ thousand	4,963	6,384	–22.3
Special effects	€ thousand	2,133	1,292	65.1
Acquisition-related PPA depreciation and amortization	€ thousand	5,964	6,075	–1.8
Adjustment for taxes on adjustments	€ thousand	–2,299	–2,087	10.2
Adjusted net income after taxes	€ thousand	10,761	11,664	–7.7
Weighted average number of shares	Number	24,514,151	25,505,723	–3.9
Earnings per share adjusted for special items	€ thousand	0.44	0.46	–4.3

3 Calculated from cash flow from operating activities less capital expenditure (CapEx).

Revenue by operating segment



EBITDA by operating segment, adjusted for special items[1]



Quarterly statement as of March 31, 2026

MEDIOS REPORTS FURTHER REVENUE GROWTH IN THE FIRST QUARTER OF 2026 AND CONFIRMS FULL-YEAR GUIDANCE

- Revenue rose to €527.6 million in the first quarter (+8.9%)
- EBITDA pre of €21.2 million is 7.9% below the level of the same quarter last year
- Cash flow from operating activities rises significantly to €12.5 million (+250.3%)
- Adjusted earnings per share €0.44 (–4.3%)
- 2026 guidance confirmed

The Medios Group once again grew significantly in the first quarter of 2026. Revenue increased by 8.9% to €527.6 million (Q1 2025: €484.7 million). EBITDA pre fell by 7.9% to €21.2 million during the same period (Q1 2025: €23.1 million). This decline is primarily attributable to operational and temporary special effects, as well as a one-time special gain in the prior-year period. The results for the first quarter of 2026 are in line with analyst expectations.

Consolidated earnings after tax fell by 22.3% to €5.0 million (Q1 2025: €6.4 million). Earnings per share thus stood at €0.20 (Q1 2025: €0.25), while the adjusted figure amounted to €0.44 (Q1 2025: €0.46). Cash flow from operating activities in the first quarter of 2026 reached €12.5 million (Q1 2025: €3.6 million) which was significantly higher than in the same period of the previous year. This is primarily attributable to improvements in working capital management.

SIGNIFICANT EVENTS

Entry into the medical cannabis market

The Medios Group expanded its product portfolio in the first quarter of the 2026 financial year and entered the medical cannabis market. To this end, Medios is partnering with the Dutch Company Bedrocan International B.V. ("Bedrocan"), a leading international manufacturer of pharmaceutical-grade medical cannabis. Medios has secured the exclusive distribution rights for Bedrocan products in the markets of Germany, Spain, Belgium, Italy, and Austria. The agreement initially covers medical cannabis from Bedrocan's EU-GMP-[1]-certified production facility in Denmark and will be expanded to include products from all other Bedrocan production facilities starting January 1, 2027.

Medical cannabis is used in particular to treat patients with chronic pain, neurological disorders, spasticity, nausea, and loss of appetite associated with serious illnesses, and can thus represent an important therapeutic complement in various existing indication areas for Medios. With this market entry, Medios is tapping into an attractive growth market, strengthening its position as a Specialty Pharma provider, and expects to benefit from the increasing demand for high-quality, reimbursable cannabis-based medicines in Europe.

[1] European Union Good Manufacturing Practice

Change in the finance department: Stefan Bauerreis succeeds Falk Neukirch

On March 26, 2026, the Supervisory Board of Medios AG announced that it had appointed Stefan Bauerreis as a member of the Executive Board and as the company's new Chief Financial Officer (CFO), effective April 15, 2026. Stefan Bauerreis succeeds Falk Neukirch, who – as announced on March 6, 2026 – has left the Medios Group at his own request.

With the appointment of Stefan Bauerreis, Medios has gained an experienced finance expert with many years of international leadership experience in industry and at publicly traded companies. Among other roles, he served as Chief Financial Officer of the Stabilus Group and held various senior finance positions within the Schaeffler Group for more than two decades, including as CFO for the Europe and Germany region. Stefan Bauerreis possesses comprehensive expertise in traditional finance functions –, accounting, controlling, taxation, and financing – as well as in the areas of IT, M&A, and the transformation and management of international companies.

POSITION OF THE MEDIOS GROUP

Earnings position of the Medios Group (IFRS)

In the first three months of the 2026 financial year, the Medios Group recorded revenue growth of €43.0 million, or 8.9%, to €527.6 million (Q1 2025: €484.7 million).

The Pharmaceutical Supply segment generated external revenue of €424.3 million in the first quarter of 2026 (Q1 2025: €389.2 million), representing an increase of €35.0 million, or 9.0%, compared to the same period in the previous year, mainly driven by higher revenue in the wholesale business.

The Patient-Specific Therapies segment significantly increased its revenue compared to the same period in the previous year by €4.7 million, or 8.4% (Q1 2025: €55.8 million), to €60.4 million, thereby also contributing to the increase in consolidated revenue.

The International Business segment increased its revenue in the first quarter of 2026 to €43.0 million, which was €3.4 million or 8.7% higher than in the same period of the previous year.

In the Services segment, external revenue of €0.1 million was generated, in line with the prior-year quarter.

The Group's gross profit increased slightly in the reporting period to €50.2 million (Q1 2025: €49.8 million). This corresponds to a gross profit margin of 9.5% (Q1 2025: 10.3%). Price declines for selected products in the Pharmaceutical Supply segment, as well as a temporary increase in material costs in the Patient-Specific Therapies and International Business segments, led to a reduction in the Group's gross profit margin.

In the Pharmaceutical Supply segment, gross profit rose by approximately €0.7 million to €16.8 million (Q1 2025: €16.2 million), representing an increase of 4.2%. At 3.6%, the gross profit margin was slightly below the prior-year level (Q1 2025: 3.8%), which is primarily attributable to a temporary market-driven decline in price levels in certain product areas.

The Patient-Specific Therapies segment generated gross profit of €14.1 million in the reporting period, in line with the prior-year level. The gross profit margin decreased by 1.1 percentage points to 22.4% in the first quarter of 2026 (Q1 2025: 23.5%), primarily as a result of regulatory actions for price control in the German pharmaceutical market, which have been in effect since November 2025 and have so far only been partially offset by cost savings. Additionally, an unfavorable product mix had a dampening effect on margin development.

The International Business segment generated gross profit of €19.1 million in the first quarter of 2026, which was only slightly below the prior-year figure of €19.3 million. The gross profit margin of the International Business segment decreased to 44.5% in the reporting period (Q1 2025: 48.7%). The material reason for the higher gross profit margin in the prior-year period was one-time income of €1.4 million from the sale of a pharmacy in the Netherlands.

The Group's personnel expenses increased by €0.7 million compared to the prior-year period to €18.0 million (Q1 2025: €17.2 million). The increase is primarily material due to general compensation trends, temporarily higher provisions for vacation and overtime due to the reporting date, and higher expenses related to equity-based compensation.

The Group's other operating expenses amounted to €13.1 million in the first quarter of 2026, representing an increase of €2.3 million, or 21.6%, compared to the comparative prior year (Q1 2025: €10.8 million). The increase in other operating expenses is primarily attributable to higher IT costs (+€0.4 million) related to the implementation of SAP S/4HANA as the new ERP system, higher costs for temporary staff (+€0.4 million), and higher office space costs (+€0.3 million).

The Group's earnings before interest, taxes, depreciation and amortization (EBITDA) decreased by €2.7 million, or 12.3%, compared with the same period in the previous year, and thus remained below the prior-year level despite higher revenue. This is primarily due to a decline in the gross profit margin and an overall increase in operating expenses, which more than offset the positive revenue trend.

EBITDA is reconciled as follows to the Group's earnings before interest, taxes, and depreciation and amortization (EBITDA pre), adjusted for special items:

in € thousand	Q1 2026	Q1 2025
EBITDA	**19,092**	**21,762**
Expenses from Stock Option Programs	245	211
Other M&A expenses	260	9
Special costs for new appointments to the Executive Board	84	0
ERP implementation costs	1,543	1,072
EBITDA pre[1]	**21,225**	**23,053**

1 Adjusted for special items.

The Medios Group's EBITDA pre decreased by €1.8 million, or 7.9%, compared to the comparative period in the previous year. This was primarily due to temporary effects, in particular a changed product mix as well as opposing one-time effects in the comparable periods. While one-time effects had a negative impact on earnings in the first quarter of 2026, the prior-year period benefited from positive one-time effects.

The Pharmaceutical Supply segment contributed €12.1 million to the Group's EBITDA pre and, despite a slight decline in the gross profit margin, achieved a year-over-year increase in earnings of €0.3 million, or 2.8% (Q1 2025: €11.8 million). Price declines for selected products at the beginning of 2026 had a dampening effect on earnings performance, meaning that revenue growth could not be fully translated into a corresponding increase in EBITDA pre.

EBITDA pre for the Patient-Specific Therapies segment, adjusted for special items, decreased by €0.9 million, or 14.4%, compared to the same period of the previous year to €5.4 million (Q1 2025: €6.3 million). Earnings performance was influenced by a lower gross margin and higher operating expenses, causing EBITDA pre to remain below the prior-year level despite revenue growth. Regulatory actions for price control in the German pharmaceutical market, which have been in effect since November 2025, one-time effects from additional payments for ancillary costs from previous years, and a temporary increase in material usage due to temporary production inefficiencies had a negative impact on earnings performance. The production inefficiencies were already resolved in the first quarter of 2026.

The International Business segment contributed €6.3 million to EBITDA pre (Q1 2025: €7.3 million). Earnings performance was influenced in particular by positive one-time effects in the prior-year period, with the sale of a pharmacy in the first quarter of 2025 resulting in a one-time positive earnings effect of €1.4 million. In addition, temporarily higher material costs related to eye injections had a negative impact on earnings performance in the first quarter of 2026.

EBITDA pre for the Services segment amounted to €–2.6 million in the first quarter of 2026, roughly on par with the prior-year period (€–2.4 million).

Depreciation and amortization in the first quarter of 2026 totaled €9.4 million (Q1 2025: €9.5 million) and included, in addition to scheduled depreciation and amortization of property, plant and equipment and intangible assets, scheduled acquisition-related PPA[2] amortization of €6.0 million (Q1 2025: €6.1 million). Depreciation and amortization for capitalized leasehold rights amounted to €1.2 million (Q1 2025: €1.4 million).

The Medios Group's financial result improved by €1.5 million compared to the prior-year period to €–1.4 million (Q1 2025: €–2.9 million). This was primarily due to lower financial expenses resulting from a reduced loan portfolio following the scheduled repayment of the term loan, as well as a lower reference interest rate and decreased interest margins due to an improved debt-to-equity ratio. In addition, higher financial income from the revaluation of derivative financial instruments measured at fair value had a positive impact on the financial result.

Tax expense increased in the reporting period compared with the same period of the previous year, despite lower pre-tax earnings, primarily due to offsetting non-recurring effects from prior periods. While non-recurring tax income of €0.4 million reduced the tax rate in the prior-year period, non-recurring tax expenses in the current reporting period led to a higher tax rate of 40.3% (Q1 2025: 31.8%).

Earnings after taxes in the first quarter of 2026 were thus €5.0 million, below the prior-year level (Q1 2025: €6.4 million).

Earnings per share thus stood at €0.20 per share in the first quarter of 2026 (Q1 2025: €0.25 per share), representing a decline of 20.0%. In contrast, adjusted earnings per share were €0.44 per share (Q1 2025: €0.46 per share), remaining roughly on par with the same period last year.

Financial position of the Medios Group (IFRS)

Cash and cash equivalents amounted to €92.9 million as of March 31, 2026 (December 31, 2025: €81.8 million) and consisted primarily of freely available bank balances. The €11.1 million increase in cash and cash equivalents compared to the end of 2025 is attributable to the following material cash flows:

Cash flow from operating activities amounted to €12.5 million and was significantly higher than the prior-year figure (Q1 2025: €3.6 million). The Medios Group's working capital management contributed significantly to this positive development, which is primarily attributable to a substantially lower increase in net working capital as

[2] Purchase Price Allocation

of the balance sheet date of March 31, 2026, compared to March 31, 2025. By contrast, a lower consolidated net income and higher tax payments compared to the prior year had an offsetting effect.

Cash outflows from investing activities in the first quarter of 2026 amounted to €2.1 million (cash inflows in Q1 2025: €0.4 million) and resulted primarily from payments for investments in fixed assets totaling €2.6 million (Q1 2025: €1.2 million). This was offset by interest received of €0.2 million (Q1 2025: €0.1 million) and disposals of fixed assets totaling €0.2 million (Q1 2025: €0.6 million).

The net cash inflow from financing activities amounted to €0.6 million in the first quarter of 2026 (Q1 2025: €–21.0 million). This resulted primarily from cash inflows from the net drawdown of an additional tranche of the revolving credit facility (RCF) in the amount of €10.0 million. This was offset by cash outflows, in particular from the scheduled repayment of the term loan in the amount of €6.3 million (Q1 2025: €6.3 million), from interest paid in the amount of €1.8 million (Q1 2025: €3.4 million) in connection with the utilized credit facilities, and from principal payments on leasing liabilities amounting to €1.3 million (Q1 2025: €1.3 million).

Net assets of the Medios Group (IFRS)

The Group's balance sheet total increased by €15.2 million as of March 31, 2026, compared to December 31, 2025, to €918.2 million (December 31, 2025: €903.0 million).

The carrying amount of intangible assets as of March 31, 2026, decreased by a total of €6.1 million compared to December 31, 2025, primarily due to scheduled depreciation and amortization of customer bases and other intangible assets in the amount of €6.4 million.

Property, plant and equipment increased by €0.4 million to €41.5 million compared to December 31, 2025, as investments exceeded scheduled depreciation and amortization. Capitalized leasehold rights decreased compared to December 31, 2025, primarily due to scheduled depreciation and amortization.

Current assets increased by €22.2 million to €365.8 million as of the balance sheet date (December 31, 2025: €343.7 million) and is primarily attributable to an increase in trade receivables as of the balance sheet date (+€25.3 million) and a €11.0 million increase in cash and cash equivalents. Conversely, income tax receivables decreased by €6.0 million to €2.4 million (December 31, 2025: €8.4 million) and inventories decreased by €6.1 million to €87.2 million (December 31, 2025: €93.3 million).

As of March 31, 2026, shareholders' equity amounted to €519.7 million, representing an increase of €5.5 million compared with the end of 2025 (December 31, 2025: €514.2 million). As part of an equity-based compensation payment, treasury shares were transferred to a Member of the Executive Board. As a result, the deduction for treasury shares in equity decreased by €0.2 million to €–12.4 million as of the balance sheet date (December 31, 2025: €12.6 million). The equity ratio stood at 56.6% as of March 31, 2026 (December 31, 2025: 56.9%).

Non-current liabilities increased by €0.9 million as of the balance sheet date to €208.4 million (December 31, 2025: €207.5 million). This was primarily due to the net drawdown of an additional tranche of the revolving credit facility (RCF) in the amount of €10.0 million, which was partially offset by the scheduled repayment of the term loan (€6.3 million) and the reduction in leasing liabilities (€1.3 million).

Current liabilities increased by €8.8 million compared to December 31, 2025, to €190.1 million (December 31, 2025: €181.3 million). This was primarily due to a higher balance of trade payables as of the reporting date (+€3.3 million) and increased other current liabilities (+€8.8 million), mainly related to provisions for outstanding invoices and personnel provisions. This was offset by lower income tax liabilities (–€3.5 million).

Positive outlook for the 2026 financial year

For the 2026 financial year, the Executive Board expects revenue of €2.0 billion to €2.12 billion and EBITDA pre of €94 million to €102 million. This would correspond to an increase in the EBITDA pre margin to approximately 4.8%. The forecast is based on a number of forward-looking assumptions, including moderate revenue growth, gross profit growth, and resulting organic EBITDA pre growth in the mid-single-digit percentage range. Personnel costs are expected to rise by approx. 9%. For other operating expenses, the Medios Group anticipates a decrease of approx. 7%, primarily due to the planned replacement of some temporary staff with direct hires. Should material assumptions prove inaccurate, an adjustment to the forecast cannot be ruled out. The extraordinary expenses adjusted in the EBITDA pre-forecast for 2026 primarily include expenses for stock options, expenses for the implementation of an ERP system, and expenses for M&A.

Consolidated statement of comprehensive income

in € thousand	Q1 2026	Q1 2025	Δ in %
Revenue	**527,621**	**484,657**	**8.9**
Change in inventory of finished/unfinished products	–47	1,333	<–100
Other income	232	1,923	–87.9
Cost of materials	477,645	438,146	9.0
Personal expenses	17,981	17,238	4.3
Other expenses	13,088	10,768	21.5
Earnings before interest, tax, depreciation and amortization	**19,092**	**21,762**	**–12.3**
Depreciation and amortization	9,357	9,453	–1.0
Operating profit/loss	**9,735**	**12,309**	**–20.9**
Financial expenses	1,906	3,150	–39.5
Financial income	481	202	>100
Financial result	–1,425	–2,948	–51.7
Consolidated earnings before tax	**8,310**	**9,361**	**–11.2**
Income taxes	3,347	2,977	12.4
Consolidated earnings after tax	**4,963**	**6,384**	**–22.3**
Total consolidated earnings			
Undiluted earnings per share (in €)	0.20	0.25	–20.0
Diluted earnings per share (in €)	0.20	0.25	–20.0

Consolidated balance sheet

Assets

in € thousand	03/31/2026	12/31/2025	Δ in %
Non-current assets	**552,376**	**559,385**	**–1.3**
Intangible assets	478,529	484,643	–1.3
Property, plant and equipment	41,452	41,024	1.0
Rights of use as a lessee	30,791	32,029	–3.9
Financial assets	1,604	1,690	–5.1
Current assets	**365,850**	**343,657**	**6.5**
Inventories	87,200	93,318	–6.6
Trade receivables	168,051	142,713	17.8
Short-term financial assets	748	884	–15.4
Other assets	14,213	16,097	–11.4
Income tax receivables	2,428	8,445	–71.2
Cash and cash equivalents	92,854	81,844	13.5
Non-current assets held for sale	355	355	0.0
Balance sheet total	**918,226**	**903,041**	**1.7**

Liabilities

in € thousand	03/31/2026	12/31/2025	Δ in %
Equity			
Paid-in capital	25,506	25,506	0.0
Capital reserve	407,867	407,525	0.1
Accumulated consolidated net income	98,732	93,768	5.3
Treasury shares	–12,409	–12,580	–1.4
Attributable to shareholders in the parent company	**519,696**	**514,219**	**1.1**
Liabilities			
Long-term liabilities	**208,445**	**207,514**	**0.4**
Financial liabilities	172,669	170,186	1.5
Other provisions	4,140	4,099	1.0
Deferred tax liabilities	31,635	33,230	–4.8
Short-term liabilities	**190,085**	**181,308**	**4.8**
Other provisions	1,831	1,779	2.9
Trade payables	93,700	90,423	3.6
Financial liabilities	30,024	31,604	–5.0
Income tax liabilities	28,671	32,128	–10.8
Other liabilities	33,659	24,999	34.6
Advance payments received	2,201	375	>100
Total Liabilities	**398,530**	**388,822**	**2.5**
Balance sheet total	**918,226**	**903,041**	**1.7**

Consolidated statement of cash flows

in € thousand	Q1 2026	Q1 2025	Δ in %
Cash flow from operating activities			
Consolidated earnings after tax	4,963	6,384	–22.3
Depreciation and amortization	9,357	9,453	–1.0
Decrease/Increase in provisions	57	–198	<–100
Other cash expenses	358	211	69.7
Increase in inventories, trade receivables, and other assets not attributable to investments or financing activities	–16,869	–27,771	–39.3
Decrease/increase in trade payables and other liabilities not attributable to Investments or financing activities	12,222	8,601	42.1
Financial result	1,425	2,948	–51.7
Gains/losses on the disposal of assets	0	–1,405	–100.0
Income tax expense	3,347	2,977	12.4
Income tax payments	–2,381	2,363	<–100
Net cash flow from operating activities	**12,480**	**3,563**	**>100**
Cash flow from investment activities			
Payments for investments in intangible assets	–519	–278	86.7
Proceeds from disposals of intangible assets	156	10	>100
Payments for investments in property, plant, and equipment	–2,075	–968	>100
Proceeds from disposals of property, plant, and equipment	10	614	–98.4
Proceeds from disposals of long-term financial assets	100	82	22.0
Payments for investments in long-term financial assets	–14	–13	7.7
Payments for additions to the scope of consolidation	0	–1,505	–100.0
Proceeds from disposals from the scope of consolidation	3	2,360	–99.9
Interest received	240	87	>100
Net cash outflow from investing activities	**–2,100**	**387**	**<–100**
Net cash inflow from financing activities			
Proceeds from the issuance of debt	14,932	20,000	–25.3
Payments made to repay financial liabilities	–11,289	–36,282	–68.9
Interest paid	–1,761	–3,425	–48.6
Repayments of lease liabilities	–1,255	–1,310	–4.2
Net cash inflow from financing activities	**627**	**–21,017**	**<–100**
Net change in cash and cash equivalents	11,007	–17,067	<–100
Cash and cash equivalents at the beginning of the period	81,844	106,224	–23.0
Cash and cash equivalents at the end of the period	**92,854**	**89,157**	**4.1**

Consolidated statement of changes in equity

in € thousand	Paid-in capital	Capital reserve	Accumulated consolidated net income	Treasury shares	Attributable to shareholders in the parent company	Equity
As of January 1, 2025	**25,506**	**406,283**	**78,403**	**0**	**510,192**	**510,192**
Total consolidated earnings 2025			6,384		6,384	6,384
Share-based payments					211	211
As of March 31, 2025	**25,506**	**406,494**	**84,788**	**0**	**516,787**	**516,787**
As of January 1, 2026	**25,506**	**407,525**	**93,768**	**–12,580**	**514,219**	**514,219**
Total consolidated earnings 2026			4,963		4,963	4,963
Share-based payments		338			338	338
Share-based payment settled by issuing treasury shares		4		171	175	175
As of March 31, 2026	**25,506**	**407,867**	**98,732**	**–12,409**	**519,696**	**519,696**

This quarterly report was published on May 12, 2026.

Contact
Claudia Nickolaus
Head of Investor & Public Relations

Medios AG
Heidestraße 9 | 10557 Berlin
T +49 30 232 566 800
c.nickolaus@medios.group
www.medios.group

Disclaimer

This announcement contains forward-looking statements that are subject to certain risks and uncertainties. Future results may differ materially from those currently expected due to various risk factors and uncertainties, such as changes in the business, economic, and competitive environment, exchange rate fluctuations, uncertainties regarding legal disputes or investigations, and the availability of financial resources. Medios AG assumes no responsibility for updating the forward-looking statements contained in this press release.